Costantino Pitzalis is Versus Arthritis Professor of Rheumatology at the William Harvey Research Institute, Barts and The London School of Medicine and Dentistry Queen Mary University of London, London, UK, and Deputy Director of the William Harvey Research Institute and Chair of the National Institute for Health Research Musculoskeletal Translational Research Collaboration (NIHR MSK TRC) in London. He is also Head of the Centre for Experimental Medicine and Rheumatology at the William Harvey Reseach Institute, leading a research team of approximately 50 researchers (clinicians and scientists).
Professor Pitzalis’s research interests focus on the cellular and molecular mechanisms of inflammation and autoimmunity in chronic rheumatic conditions, particularly rheumatoid arthritis (RA). He is the Chief Investigator of a comprehensive biopsy-driven stratified-medicine randomized clinical trials (RCTs) programme funded by the Medical Research Council/Versus Arthritis and the NIHR. These RCTs are the first worldwide biopsy-driven trials that span the disease course from early to late RA and are synchronized for drug exposure. This programme has led to the definition of specific pathobiological phenotypes linked to clinical and treatment response endotypes in early arthritis (published in Cell Reports in 2019) and in anti-tumour necrosis factor inadequate responder patients (published in the Lancet in 2021). The ultimate goal of the programme is the delineation of synovial-specific signatures able to define a new taxonomy of disease integrating clinical and molecular pathology algorithms to more accurately predict prognosis and treatment response prior to the initiation of potentially toxic and expensive therapies, in order to give the right drug to the right patients first time: towards precision medicine.
Professor Pitzalis has published over 290 peer-reviewed papers in the field of inflammation, immunity, and arthritis.
EM-59313 - Date of preparation: May 2021